Pharmaceutical Lifecycle Management (eBook)
412 Seiten
John Wiley & Sons (Verlag)
978-1-118-26679-3 (ISBN)
The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can--and must--do to get the most out of their brands.
Offering a truly immersive introduction to LCM options for pharmaceuticals, the book incorporates numerous real-life case studies that demonstrate successful and failed lifecycle management initiatives, explaining the key takeaway of each example. Filled with practical information on the process of actually writing and presenting an LCM plan, as well as how to link corporate, portfolio, and individual brand strategies, the book also offers a look ahead to predict which LCM strategies will continue to be effective in the future.
While the development of new drugs designed to address unmet patient needs remains the single most important goal of any pharmaceutical company, effective LCM is invaluable for getting the greatest possible value from existing brands. Pharmaceutical Lifecycle Management walks you through the process step by step, making it indispensable reading for pharmaceutical executives and managers, as well as anyone working in the fields of drug research, development, and regulation.
TONY ELLERY is a consultant with Ellery Pharma Consulting. Until September 2008, he was the Head of Pharmaceutical Lifecycle Management in Portfolio Management at Novartis AG. Prior to this, he occupied positions of increasing seniority in research, development, and marketing at different companies, including Roche, Ciba Vision, and Novartis. Dr. Ellery has served as a member of the Ciba-Geigy Research Advisory Board and the Novartis Pharma Development Management Board. He is a popular speaker on lifecycle, project, and portfolio management. NEAL HANSEN is the Managing Director of Healthcare Consulting within the Informa Group, encompassing Datamonitor Healthcare Consulting and Phasic Strategy. Previously, he was the European Head of Consulting within Wood Mackenzie's Life Sciences Practice. He works with many key players in the pharmaceutical industry to support effective decision making for brand and portfolio strategy and has chaired and spoken at numerous conferences in the field of lifecycle management and the changing nature of the generic drug industry.
Introduction 15
Section A. Lifecycle Management Business Environment 17
Chapter 1. Challenges facing the branded pharmaceutical industry 17
Chapter 2. The lifecycle of industries, technologies and brands 32
Chapter 3. The lifecycle of a pharmaceutical brand 36
Section B. Lifecycle Management Regulatory and Legal Environment 45
Chapter 4. The generic approval process 45
Chapter 5. Hatch-Waxman Legislation and its effects on LCM 48
Section C. Patents and Exclusivities 56
Chapter 8. Patents and other property rights 56
Chapter 9. Non-patent exclusivities 67
Chapter 10. Developmental settlements 72
Section D. Developmental LCM 75
Chapter 11. Strategic principles of developmental LCM 75
Chapter 12. Indication expansion and sequencing 79
Chapter 13. Patient subpopulations and personalized medicine 83
Chapter 14. New dosage strengths, new dosage regimens 89
Chapter 15. Reformulation, new routes of administration and drug delivery 91
Chapter 16. Fixed-dose combinations (FDCs) and Co-packaging 96
Chapter 17. Second Generation Products and Modified Chemistry 99
Chapter 18. Other development LCM strategies 102
Section E. Commercial LCM 104
Chapter 19. Strategic principles of commercial LCM 104
Chapter 20. Geographical expansion and optimization 106
Chapter 21. OTC switching 109
Chapter 22. Brand loyalty and service programmes 113
Chapter 23. Strategic pricing strategies 115
Section F. Biologics and Biosimilars 124
Chapter 26. Biologics and LCM 124
Chapter 27. Biosimilars and their impact on biologic LCM 129
Section F. The Integrated Brand LCM Strategy and Its Implementation 137
Chapter 28. Strategic goals on LCM brand plans 138
Chapter 29. Ten Keys to Successful LCM 141
Chapter 30. Organizational structures and systems for ensuring successful LCM 150
Chapter 31. The LCM process - description, timing and participants 158
Section G. Integrating LCM with Portfolio Management 163
Chapter 32. Principles of Portfolio Management 164
Chapter 33. LCM projects in the development portfolio 166
Chapter 34. Managing Established Brand Portfolios 167
Conclusions 170
Appendix - Case Histories 173
"In conclusion, it should be stated that the authors
reached their goals in providing a reference manual for potential
measures that should be applied in case the life and profit of a
brand are to be maximized." (Green Processing and
Synthesis, 1 March 2014)
| Erscheint lt. Verlag | 17.4.2012 |
|---|---|
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Medizin / Pharmazie ► Pharmazie | |
| Naturwissenschaften ► Chemie | |
| Technik | |
| Wirtschaft ► Betriebswirtschaft / Management ► Marketing / Vertrieb | |
| Schlagworte | Business & Management • Chemie • Chemistry • Drug Discovery & Development • Industrial Engineering • Industrial Engineering / Project Management • Industrielle Verfahrenstechnik • Projektmanagement i. d. Industriellen Verfahrenstechnik • Strategic Marketing • Strategisches Marketing • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung • Wirtschaft u. Management |
| ISBN-10 | 1-118-26679-X / 111826679X |
| ISBN-13 | 978-1-118-26679-3 / 9781118266793 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 3,4 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
